Noninvasive imaging-based vascular score is associated with immunotherapy outcome in non-small cell lung cancer
“Morphological abnormality in tumor vasculature, a recently recognized mechanism of resistance to immune checkpoint inhibitors (ICIs), remains difficult to quantify due to its heterogeneity. We present the vascular risk score (VRS), a deep learning–based imaging metric that quantifies abnormalities in tumor vasculature on CT scans.”
Exploring the Underreporting of Lambert-eaton Myasthenic Syndrome in Small Cell Lung Cancer
“Among 564 SCLC patients, only two (0.35%) had a recorded LEMS diagnosis. This is nearly tenfold lower than the expected 3–4% prevalence, indicating substantial underreporting. LEMS was documented in 14 patients overall, with 50% associated with malignancy.”
FIU researcher uses mathematics to improve lung cancer screenings
“Sept. 9, 2026 — A new model developed by Florida International University researcher Deborah Goldwasser uses mathematical modeling to pinpoint the critical window when an aggressive lung tumor is still curable. The findings could help refine lung cancer screening strategies and identify cancers before they cross that threshold, leading to more personalized screening schedules. This would allow patients at higher risk of developing fast-growing tumors to be monitored more frequently while reducing unnecessary screenings for others.”
AbbVie’s Bet on Biology: Why One Modality Is Never Enough in Lung Cancer
“Lung cancer remains one of the hardest cancers to treat, despite major advances in targeted therapy and immunotherapy. At WCLC 2026, AbbVie is presenting new clinical and translational research across its lung cancer pipeline, including first-line Phase 1b data for the investigational PD-1/VEGF bispecific ABBV-1480 and new research around the SEZ6-targeted antibody-drug conjugate (ADC) ABBV-706.”
SPP1 overexpression is linked to unfavorable outcomes in patients with ALK/TP53 co-mutated lung cancer
“Patients with ALK/TP53 co-mutated lung cancer experience notably worse progression-free survival (PFS) and overall survival (OS) than those with TP53 wildtype. Nevertheless, the precise molecular mechanism underlying poor survival of patients with ALK/TP53 co-mutated lung cancer is unclear.”
Updated Data Show Targeted Drug Ibtrozi Can Keep ROS1-Positive Lung Cancer Under Control For Longer
“The Food and Drug Administration approved an update to the label for a targeted drug called taletrectinib (brand name: Ibtrozi) after trial data showed it helped keep a subtype of lung cancer controlled for an average of more than 4 years.”
Annual Report to the Nation: Progress Against Lung Cancer Drives Down Cancer Mortality
“Cancer death rates fell for both men and women from 2019 to 2023, continuing a downward trend that has lasted more than 20 years, according to the 2026 Annual Report to the Nation on the Status of Cancer, published in the journal Cancer. The continued decline in cancer deaths is driven largely by accelerated progress against lung cancer.”
Why Some Stage 3 Lung Cancers Don’t Respond to Treatment, and What Researchers Are Trying Next
“Key Takeaways: Concurrent chemoradiation followed by durvalumab yields objective responses in only ~30% of stage III unresectable NSCLC, while toxicity and normal-tissue constraints preclude meaningful radiation dose escalation beyond ~60 Gy. Hafnium oxide nanoparticles (JNJ-1900/NBTXR3) are intended to intensify radiation-mediated cytotoxicity by augmenting damage generated within tumor water, potentially improving local effect without higher external beam dose.”
Active Surveillance Shows Survival Benefit in Non-Small Cell Lung Cancer
“Among patients receiving care for non-small cell lung cancer (NSCLC), active post-treatment imaging surveillance is significantly associated with decreased mortality risk, according to study findings published in The Journal of Thoracic and Cardiovascular Surgery.”
Iterion Therapeutics Announces Promising Phase 1b Data for Tegavivint in Combination with Osimertinib in First-Line EGFR-Mutated Non-Small Cell Lung Cancer
“Combination demonstrating 79% objective response rate (ORR), including complete responses (CRs) in 16% of patients (compared to 1% historically for osimertinib alone). Median progression-free survival (mPFS) of 19.9 months and median overall survival (mOS) of 48.8 months observed in the dose-escalation cohort (compared to 37.6 months OS historically for osimertinib alone). Combination was well tolerated, with no dose-limiting toxicities. Data provide clinical support for targeting β-catenin-mediated drug-tolerant persister cells as a strategy to improve the depth and durability of response to EGFR-targeted therapy.”
